SNTI Stock Overview
Operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Senti Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.14 |
| 52 Week High | US$16.94 |
| 52 Week Low | US$1.52 |
| Beta | 2.7 |
| 1 Month Change | 96.21% |
| 3 Month Change | 83.19% |
| 1 Year Change | -29.95% |
| 3 Year Change | -95.80% |
| 5 Year Change | n/a |
| Change since IPO | -95.85% |
Recent News & Updates
Recent updates
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Dec 28
Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?
Sep 27Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform
Sep 22Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M
Aug 16Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Jun 13Shareholder Returns
| SNTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.0% | 2.6% | 2.8% |
| 1Y | -29.9% | -3.3% | 24.6% |
Return vs Industry: SNTI underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: SNTI underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| SNTI volatility | |
|---|---|
| SNTI Average Weekly Movement | 103.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNTI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SNTI's weekly volatility has increased from 54% to 104% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 48 | Tim Lu | www.sentibio.com |
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Senti Biosciences, Inc. Fundamentals Summary
| SNTI fundamental statistics | |
|---|---|
| Market cap | US$19.13m |
| Earnings (TTM) | -US$70.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs SNTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNTI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$35.71m |
| Gross Profit | -US$35.71m |
| Other Expenses | US$35.16m |
| Earnings | -US$70.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 04:40 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Senti Biosciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Lut Ming Cheng | J.P. Morgan |